SCHEMBL533531

SCHEMBL533531

CC(C)COc1ccc2c[c]sc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 2/20 0.40
ABL1 P00519 2/20 0.37
HPGD P15428 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PDK2 Q15119 1/20 0.35
MAOA P21397 1/20 0.35
TRIM24 O15164 1/20 0.35
XBP1 P17861 1/20 0.34
TARBP2 Q15633 1/20 0.34
SRC P12931 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533036 0.82 KMT2A (0.46) HPGDKDM4EALDH1A1MAPTCYP2C9
SCHEMBL533265 0.79 CA12 (0.48) ALDH1A1MAPTCYP2C9CYP2C19NPC1
SCHEMBL533037 0.79 CA12 (0.48) HPGDKDM4EALDH1A1MAPTLMNA
SCHEMBL533913 0.79 ALDH1A1 (0.39) ABL1HPGDKDM4EALDH1A1POLB
SCHEMBL534840 0.77 CA12 (0.46) TSHRMAOACA2
SCHEMBL533227 0.77 GPBAR1 (0.38) MAPTNPC1RAB9A
SCHEMBL533031 0.76 CYP1A2 (0.45) HPGDKDM4EALDH1A1POLBMAPT
SCHEMBL534319 0.76 NR5A1 (0.45) TSHRMAOACA2
SCHEMBL534075 0.72 KIF11 (0.35) ABL1CYP2C9LMNANPC1RAB9A
SCHEMBL533424 0.72 ALOX15 (0.34) ABL1HPGDALDH1A1MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 EP disclosed
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE INDUSTRIES, LTD. (JP) 2014-04-24 US disclosed
US-8648097-B2 Pyridylaminoacetic acid compound UBE INDUSTRIES, LTD. (JP) 2014-02-11 US disclosed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US disclosed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP disclosed
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE CORPORATION (JP) 2011-03-03 US disclosed
EP-2264009-A1 PYRIDYLAMINOACETIC ACID COMPOUND Ube Industries, Ltd. (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113907-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 XDH 1739/4885ABL1 2803/4885HPGD 261/4885
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND PTGER2, PTGER1, PTGDR2 XDH 1723/4885ABL1 3139/4885HPGD 313/4885
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 XDH 837/4885ABL1 2982/4885HPGD 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.